Mergen.financeEdwards Lifesciences
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sept | Oct | Nov | Dec | Year |
|---|
| 2026 | ▼ 4.6% | ▲ 6.3% | ▼ 7.4% | ▲ 4.3% | ▲ 3.6% | ▲ 4.6% | ▼ 4.9% | ▲ 5.4% | ▼ 4.9% | ▲ 6.6% | ▲ 3.5% | ▲ 11.7% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ▼ 1.6% |
From our own closes, each month-end against the previous month-end. Colour saturates at ▲ 6.6%; an empty cell means no data, a dash means we declined to derive one.
Fiscal period: FY · 2025-12-31 (10-K) — annual data, not TTM · USD · Source: SEC EDGAR (public domain)
Balance-sheet lines and ratios (assets, equity, ROE, ROA, net margin, debt/equity) open on the paid plans. See the plans